Industry News
Published study validates MammaPrint test for long-term prediction of breast cancer outcome
Feb 19, 2014
A newly published study concludes that the MammaPrint® breast cancer test can accurately stratify a woman's breast cancer risk for up to 25 years after she is first diagnosed with the disease. U.S. and Dutch researchers reported the longest-term follow-up study of its kind that confirms the durable accuracy of a unique genomic test for early-stage breast cancer. Read More
HIV drug used to reverse effects of virus that causes cervical cancer
Feb 19, 2014
A commonly-used HIV drug has been shown to kill-off the human papilloma virus (HPV) that leads to cervical cancer in a world-first clinical trial led by The University of Manchester with Kenyatta National Hospital (KNH) in Nairobi. Read More
Published study validates MammaPrint test for long-term prediction of breast cancer outcome
Feb 19, 2014
A newly published study concludes that the MammaPrint® breast cancer test can accurately stratify a woman's breast cancer risk for up to 25 years after she is first diagnosed with the disease. U.S. and Dutch researchers reported the longest-term follow-up study of its kind that confirms the durable accuracy of a unique genomic test for early-stage breast cancer. Read More
Infected Tasmanian Devils reveal how cancer cells evolve in response to humans
Feb 19, 2014
Tasmanian Devil Facial Tumour Disease (DFTD) has ravaged the world's largest carnivorous marsupial since it emerged in 1996, resulting in a population decline of over 90%. Read More
Novel study first to demonstrate the effect of laminin-5 gamma-2 on cells affected by anaplastic thyroid carcinoma
Feb 19, 2014
Anaplastic thyroid carcinoma (ATC) is an aggressive type of cancer with a poor prognosis for which there is currently no effective treatment. Researchers from the National University of Singapore (NUS) have discovered for the first time that an epithelial basement membrane protein, called laminin-5 gamma-2 (LAMC2), has the potential to be an ideal target for the treatment of ATC. Read More
New drug 'selectively kills dormant cancer cells'
Feb 19, 2014
New research published in Nature Communications details the discovery of a potential new drug that selectively kills dormant cancer cells in tumors by inducing mitochondrial dysfunction.The research team, led by Prof. Read More
Predicting presence of breast cancer through small non-coding RNAs
Feb 19, 2014
Small non-coding RNAs can be used to predict if individuals have breast cancer conclude researchers who contribute to The Cancer Genome Atlas project. The results, which are published in EMBO Reports, indicate that differences in the levels of specific types of non-coding RNAs can be used to distinguish between cancerous and non-cancerous tissues. Read More
Targeting stem cells in triple-negative breast cancer
Feb 19, 2014
New research from the University of Michigan Comprehensive Cancer Center and Georgia Regents University finds that a protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells. This provides a potential target for treating triple negative breast cancer, the most aggressive form of the disease. Read More
New drug 'selectively kills dormant cancer cells'
Feb 19, 2014
New research published in Nature Communications details the discovery of a potential new drug that selectively kills dormant cancer cells in tumors by inducing mitochondrial dysfunction.The research team, led by Prof. Read More
Predicting presence of breast cancer through small non-coding RNAs
Feb 19, 2014
Small non-coding RNAs can be used to predict if individuals have breast cancer conclude researchers who contribute to The Cancer Genome Atlas project. The results, which are published in EMBO Reports, indicate that differences in the levels of specific types of non-coding RNAs can be used to distinguish between cancerous and non-cancerous tissues. Read More
Previous Page Next Page